ERBB2 and breast cancer: In this translational study from the POETIC trial, we aim to assess the changes in gene expression profiles following 2 weeks (2wk) of AI therapy and to investigate whether on-treatment molecular characteristics provide superior prognostic value compared to baseline features in ER+/HER2+ BC.